Form 4: CFO Benjamin Hohl Sells ELVN Shares Under 10b5-1 Plan

Enliven Therapeutics CFO Benjamin Hohl exercised options and sold 3,250 shares of common stock for a significant gain under a pre-arranged 10b5-1 trading plan.

Summary

• Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics, Inc. (ELVN), executed transactions involving the company's common stock.
• On August 27, 2025, Hohl exercised stock options to acquire 3,250 shares of common stock at an exercise price of $2.48 per share.
• Immediately following the exercise, Hohl sold all 3,250 shares at a weighted average price of $20.6273 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023.
• The shares subject to the exercised option were fully vested and exercisable as of the transaction date.
• Following these transactions, Hohl directly owns 23,000 shares of common stock and 108,306 stock options.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction under a pre-arranged plan, not indicative of positive or negative company performance. The sale represents a planned liquidity event for the CFO.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned sale rather than an immediate reaction to new, undisclosed information.
• The sale price of $20.6273 per share is significantly higher than the exercise price of $2.48, indicating a substantial personal gain for the CFO.

Negatives

• An insider sale, even if pre-planned, reduces the insider's direct equity stake, which can sometimes be perceived with slight caution by the market.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide information directly related to broader industry trends or the competitive landscape. Insider sales under a 10b5-1 plan are common across all sectors, including biotechnology, for executive compensation and liquidity management.

Comparison to Industry Standards

• This filing is a standard insider transaction disclosure. There are no specific company or project results to compare against industry benchmarks.
• The execution of transactions under a Rule 10b5-1 plan is a common practice among executives in publicly traded companies across all industries, including biotechnology, to manage personal finances while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders: The sale by a CFO, even if pre-planned, might be viewed with slight caution, though the 10b5-1 plan mitigates concerns about opportunistic selling. The remaining beneficial ownership still aligns the CFO's interests with shareholders.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction by the CFO under a pre-arranged 10b5-1 trading plan. Such planned sales are common for executive compensation and personal liquidity management and typically do not reflect a change in the company's fundamental outlook or the insider's confidence. The significant gain realized by the CFO from the option exercise and sale is positive for the individual but does not provide new information to warrant a change in investment recommendation for the stock itself. Therefore, a 'hold' recommendation is appropriate as this filing does not present new material information to alter an existing investment thesis.

Keywords

Enliven Therapeutics, ELVN, Benjamin Hohl, CFO, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Beneficial Ownership